Y-mAbs Therapeutics (NASDAQ:YMAB) Earns “Outperform” Rating from Wedbush
Y-mAbs Therapeutics (NASDAQ:YMAB – Get Free Report)‘s stock had its “outperform” rating reiterated by analysts at Wedbush in a research note issued on Friday,RTT News reports. They currently have a $23.00 price objective on the stock. Wedbush’s price target indicates a potential upside of 233.82% from the stock’s previous close. A number of other equities […]
More Stories
William M. Sheriff Sells 24,000 Shares of enCore Energy Corp. (NASDAQ:EU) Stock
enCore Energy Corp. (NASDAQ:EU – Get Free Report) Director William M. Sheriff sold 24,000 shares of the company’s stock in...
Challenger Energy Group (LON:CEG) Trading 9.1% Higher – Still a Buy?
Challenger Energy Group PLC (LON:CEG – Get Free Report) traded up 9.1% on Friday . The company traded as high...
Aequus Pharmaceuticals (CVE:AQS) Sets New 52-Week Low – Should You Sell?
Aequus Pharmaceuticals Inc. (CVE:AQS – Get Free Report) shares hit a new 52-week low during mid-day trading on Wednesday ....
Vanguard S&P Small-Cap 600 Growth ETF (NYSEARCA:VIOG) Sees Unusually-High Trading Volume – What’s Next?
Shares of Vanguard S&P Small-Cap 600 Growth ETF (NYSEARCA:VIOG – Get Free Report) saw an uptick in trading volume on...
SSR Mining (NASDAQ:SSRM) Shares Up 4.8% – Still a Buy?
Shares of SSR Mining Inc. (NASDAQ:SSRM – Get Free Report) (TSE:SSO) shot up 4.8% during trading on Wednesday . The...
Boardwalk Real Estate Investment Trust (OTCMKTS:BOWFF) Hits New 52-Week Low – Here’s What Happened
Boardwalk Real Estate Investment Trust (OTCMKTS:BOWFF – Get Free Report)’s stock price hit a new 52-week low during mid-day trading...